Page last updated: 2024-11-05

trifluperidol and Huntington Disease

trifluperidol has been researched along with Huntington Disease in 1 studies

Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tarighati, S1
a'Brook, MF1

Other Studies

1 other study available for trifluperidol and Huntington Disease

ArticleYear
Trifluperidol in Huntington's chorea.
    Lancet (London, England), 1968, Aug-24, Volume: 2, Issue:7565

    Topics: Aged; Antidepressive Agents; Butyrophenones; Fluorine; Humans; Huntington Disease; Middle Aged; Pipe

1968